Three quantification assays optimized for therapeutic drug monitoring of Remicade can be used to monitor levels of the infliximab biosimilar Flixabi (sold in the United States as Renflexis).
Therapeutic drug monitoring (TDM) is increasingly considered a key step to optimizing anti—tumor necrosis factor (anti-TNF) treatment in patients with inflammatory bowel disease (IBD). The advent of biosimilars to Remicade (reference infliximab) creates the necessity of validating the utilization of Remicade-quantifying assays, which are optimized for Remicade, with biosimilar compounds.
A recent study published in Therapeutic Advances in Gastroenterology found that 3 quantification assays optimized for TDM of Remicade can be used to monitor levels of the infliximab biosimilar Flixabi (sold in the United States as Renflexis).
Portuguese researchers, led by Fernando Magro, MD, PhD, and colleagues, previously demonstrated that a number of Remicade quantification methods can be safely applied to quantify Remsima. This study extends those analyses to include Flixabi.
In addition, the researchers assessed the reactivity of anti-Remicade and anti-Remsima sera to Remicade and to its biosimilars, and showed that the anti-Remicade and anti-Remsima sera reacted to the different drugs in a similar fashion. Thus, the researchers determined the existence of Remicade, Flixabi, and Remsima cross-immunogenicity, which supports their high similarity and prevents their switching in nonresponders with antidrug antibodies.
The researchers generated sera of known concentrations of Remicade, Remsima, and Flixabi by diluting the appropriate amount of each drug into a pool of sera extracted from donor controls. Each spiked concentration was repeated between 6 and 9 times and analyzed in duplicate.
Samples were then quantified using 3 different Remicade-quantification assays: an in-house ELISA assay and 2 commercially available kits—the Quantum Blue infliximab quantitative lateral flow assay (Buhlmann; Schonenbuch, Switzerland) and the RIDASCREEN IFX monitoring (R-Biopharm, AG; Darmstadt, Germany).
All tested Remicade-infliximab-optimized assays measured Flixabi as accurately as they measured Remicade and Remsima, with intra-class correlation coefficients between theoretical and measured concentrations varying from 0.920 to 0.990. Inter-assay agreement values for the same compounds were high (intra-class correlation coefficients varied from 0.936 to 0.995).
“This study is, to our knowledge, the first to demonstrate that Remicade-optimized quantification methods can be used to measure Flixabi levels, while consolidating the previously published results concerning Remsima in this context,” the researchers conclude. “In fact, our results suggest that either R-Biopharm, Buhlmann, and the described in-house method can be used to measure Remicade biosimilars Remsima and Flixabi in an accurate fashion.” They said their findings demonstrating the existence of cross-immunogenicity between Remicade, Remsima and Flixabi is a finding that not only reinforces the similarity among these drugs, but also has some clinical implications: “Apatient medicated with Remicade or Remsima whose therapy fails due to the presence of anti-drug antibodies would not benefit from switching to Remicade, Remsima, or Flixabi.”
Reference
Magro F, Rocha C, Viera AI, et al., on behalf of the Portuguese IBD Study Group (GEDII). The performance of Remicade-optimized quantification assays in the assessment of Flixabi levels. Ther Adv Gastroenterol.2018;11:1-9. doi: 10.1177/ 1756284818796956.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.